NeuroPace (NPCE) FCF Margin Growth (1y) (2021 - 2026)
NeuroPace (NPCE) FCF Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.89 Bn | 173.59 Bn | 6.27 Bn | -80.00 |
| 2 | Stryker | 127.82 Bn | 124.94 Bn | 3.81 Bn | 473.00 |
| 3 | Medtronic | 107.49 Bn | 98.27 Bn | 6.41 Bn | -192.00 |
| 4 | Boston Scientific | 67.24 Bn | 65.78 Bn | 3.61 Bn | -431.00 |
| 5 | Edwards Lifesciences | 48.02 Bn | 44.34 Bn | 1.29 Bn | -1,716.00 |
| 6 | Dexcom | 28.25 Bn | 27.14 Bn | 750.30 Mn | 2,833.00 |
| 7 | GE HealthCare Technologies | 28.17 Bn | 25.89 Bn | 1.98 Bn | -125.00 |
| 8 | Smith & Nephew | 26.72 Bn | 26.14 Bn | - | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn | 2,811.00 |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | 620.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 620.00 |
| Dec 31, 2025 | 2,226.00 |
| Sep 30, 2025 | 172.00 |
| Jun 30, 2025 | 1,147.00 |
| Mar 31, 2025 | 822.00 |
| Dec 31, 2024 | -224.00 |
| Sep 30, 2024 | 517.00 |
| Jun 30, 2024 | 568.00 |
| Mar 31, 2024 | 2,624.00 |
| Dec 31, 2023 | 4,387.00 |
| Sep 30, 2023 | 4,830.00 |
| Jun 30, 2023 | 8,254.00 |
| Mar 31, 2023 | 3,258.00 |
| Dec 31, 2022 | 1,484.00 |
| Sep 30, 2022 | -1,913.00 |
| Jun 30, 2022 | -6,089.00 |
| Mar 31, 2022 | -4,790.00 |
| Dec 31, 2021 | -1,702.00 |
| Sep 30, 2021 | -107.00 |
| Jun 30, 2021 | -512.00 |